Shanghai Duoning Biotechnology Co., Ltd. (hereinafter referred to as: Duoning Biotechnology) is a major supplier of serum-free culture medium, disposable products and bioreactor in the domestic biomedical industry. It is committed to the development of high-quality and efficient serum-free, personalized, chemical composition limited cell culture medium and animal cell culture process; research, development and production of disposable production and bioreactor, meanwhile, provide formula production, process optimization, process validation, technical support and supporting services for the biopharmaceutical industry.
Duoning Biotechnology was founded in 2005. In 2016, Duoning Biotechnology invested in the new single-use products of China's biotechnology and pharmaceutical industry: Shanghai LePure Biotechnology Co., Ltd. In 2018, Duoning Biotechnology incorporated: the culture medium business of Beijing Tianguangshi Biotechnology Co., Ltd. (hereinafter referred to as Tianguangshi), realizing the layout of double engine R & D bases in Shanghai and Beijing. In 2019, Duoning Biotechnology realized the acquisition of Guangzhou Qizhi Bioengineering Equipment Co., Ltd. (hereinafter referred to as Qizhi). Qizhi biological was founded in 2008. It is a comprehensive bioreactor supplier integrating R & D, production and sales in China. Its main products include laboratory type, pilot test, production type cell bioreactor, microbial fermentation tank series and complete sets of equipment. Meanwhile, Qizhi provides technological services for large-scale cultivation of animal cells by cell bioreactor to produce vaccines, antibodies and other products Business.
At present, Duoning Biotechnology mainly provides basic culture media such as S3, S3-CD, S4, media C for biomedical industry customers, as well as max series, AR8 / BR8, DN feed 1 / DN feed B, 2×103 feeding media and other high-efficiency feeding medium series based on 2×103 supplements. With the development of the local biomedical industry, the company focuses on reducing the production cost of drugs, and on the principle of helping customers optimize cell culture process and win-win cooperation, customizing high-quality and personalized animal cell culture medium according to customer needs; constantly improving cell culture efficiency, reducing the cost of biopharmaceutical, and improving the comprehensive competition of local biopharmaceutical manufacturers strength. At the same time, in view of the wide application of disposable products and bioreactors in antibody drugs, research and production of disposable biopharmaceutical process equipment and consumables, the disposable process technology and advanced bioreactors will be landed in China, and relevant products will be localized.